Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics
globenewswire.com
news
2022-10-17 12:30:00

The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines



Exacis' iNK and iT cells, made using non-viral, episome-free cell engineering technology, include advanced â€˜stealthing' edits, and can target virtually any cancer antigen

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ('Eterna' or the 'Company'), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced it has entered into an option agreement with Exacis Biotherapeutics Inc.
